Literature DB >> 9139495

Measles vaccination of Thai infants by intranasal and subcutaneous routes: possible interference from respiratory infections.

S Simasathien1, S Migasena, W Bellini, R Samakoses, P Pitisuttitham, W Bupodom, J Heath, L Anderson, J Bennett.   

Abstract

Reactogenicity and seroresponses were studied after standard doses of Edmonston-Zagreb measles vaccine were given intranasally (i.n.) and subcutaneously (s.c.) to 6-month-old Thai children. Few children given i.n. vaccine (2/31), but most (13/21) given s.c. vaccine, seroconverted. All but 1 of 51 children were seropositive after receiving vaccine s.c. at 9 months-of-age. Upper respiratory infection (URI) outbreaks with onsets in the week following vaccination occurred after each vaccination session and were equally common in all groups. URIs following i.n. vaccination at 6 months may have adversely affected response to i.n. vaccine, while URIs after s.c. vaccination at 9 months adversely affected final geometric mean antibody titers. I.n. measles vaccination does not appear to be an acceptable route for routine vaccination.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9139495     DOI: 10.1016/s0264-410x(97)00104-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy.

Authors:  A P Durbin; M H Skiadopoulos; J M McAuliffe; J M Riggs; S R Surman; P L Collins; B R Murphy
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

Review 2.  [Antiviral vaccination and respiratory mucosal immunity: still disappointing results from a seductive idea].

Authors:  F Denis; S Alain; S Hantz; P Lagrange
Journal:  Presse Med       Date:  2005-10-08       Impact factor: 1.228

3.  [Immunity and antiviral vaccinations. Example: the respiratory mucosa].

Authors:  F Denis; S Hantz; S Alain
Journal:  Antibiotiques (Paris)       Date:  2008-01-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.